Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Detect InSpect ChAracterise Resect and Discard 2 (DISCARD2)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by South Tyneside NHS Foundation Trust.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
University of Durham
Information provided by (Responsible Party):
South Tyneside NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01603927
First received: May 17, 2012
Last updated: May 22, 2012
Last verified: May 2012
  Purpose

Bowel cancer is a common disorder in the UK. Most cancers happen when a type of polyp, called an adenoma, becomes cancerous. Polyps are growths in the large bowel that can be cancerous, non-cancerous, or pre-cancerous (adenoma). Polyps are most commonly detected during colonoscopy (camera test of the lower bowel). The removal of adenomas has been shown to reduce the subsequent risk of bowel cancer. Current practice is that all polyps are removed or biopsied to allow a laboratory diagnosis (histology). This is important as it influences if and when patients require follow-up colonoscopies, known as the surveillance interval. Patients with only non-cancerous polyps do not need surveillance.

A new blue light technology, called narrow band imaging (NBI), used during colonoscopy can help colonoscopists (doctor or nurse performing the procedure)differentiate between polyp types during colonoscopy. NBI is currently available in a large number of UK endoscopy units however is variably used. Studies from 'expert' centres have demonstrated that NBI allows accurate optical diagnosis of colonic polyps. Benefits of optical diagnosis include avoiding removal of non-cancerous polyps and an immediate (on the day) diagnosis for the patient including the surveillance interval.

The primary aim of this study is to evaluate the accuracy with which colonoscopists assess the required surveillance interval using optical diagnosis when compared with histology in non-expert centres. The investigators will invite 2500 patients, who have been referred for colonoscopy, to participate. Patients will undergo a routine colonoscopy the only addition being the use of NBI during the procedure. Colonoscopists will provide an optical diagnosis at the time of colonoscopy in addition to polyp removal or biopsy.

The investigators will compare surveillance intervals provided using optical diagnosis with the diagnosis from histology and thereby the accuracy with which colonoscopists can use the technology. The investigators will also calculate the cost savings to the NHS.


Condition Intervention
Colonic Polyps
Device: Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Detect InSpect ChAracterise Resect and Discard 2

Resource links provided by NLM:


Further study details as provided by South Tyneside NHS Foundation Trust:

Primary Outcome Measures:
  • The sensitivity NBI optical diagnosis in determining colonoscopy surveillance intervals. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The proportion of individuals requiring surveillance colonoscopy (according to British Society of Gastroenterology Guidelines)that are correctly identified by NBI optical diagnosis (test sensitivity).


Secondary Outcome Measures:
  • The sensitivity, specificity and accuracy of optical diagnosis on a per polyp basis. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Sensitivity, specificity and accuracy of optical diagnosis on a per-polyp basis

  • The learning curve and maintenance of accuracy of optical diagnosis. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Learning curve and maintenance of quality of optical diagnosis measured by proportion of polyps/patients diagnosed with high/low confidence.

  • The economic implications of replacing histological assessment with optical diagnosis. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Potential cost saving of optical diagnosis

  • Description of the population undergoing routine colonoscopy and prevalence of polyps and polyp type. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Proportion of patients with no polyps, small polyps, large polyps, categorised by age, gender and polyps type.


Estimated Enrollment: 2500
Study Start Date: June 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Colonoscopy with Narrow band imaging (NBI)
All patients attending for routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
Device: Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).
Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients attending for routine diagnostic or screening colonoscopy.

Criteria

Inclusion Criteria:

Phase 1

  1. Patients able to provide valid informed consent.
  2. Patients over 18 years of age.
  3. Patients attending for routine colonoscopy.

Phase 2

  1. Patient fulfils inclusion criteria for phase 1.
  2. Patients with one or more polyps under 10mm detected at colonoscopy.
  3. Patients undergoing a complete colonoscopy confirmed by photo documentation of caecal landmarks.

Exclusion Criteria:

  1. Patients with known inflammatory bowel disease (ulcerative colitis of Crohns disease) or known polyposis syndromes.
  2. Patients who lack capacity to give informed consent as assessed by the clinical study team member taking consent.
  3. Patients who are known to be pregnant (self-reported).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01603927

Contacts
Contact: Colin J Rees, MBBS, FRCP (0191) 4041000 ext 4028 colin.rees@stft.nhs.uk
Contact: Praveen T Rajasekhar, MBChB BMedSci MRCP (0191) 4041000 ext 2899 praveen.rajasekhar@nhs.net

Locations
United Kingdom
County Durham and Darlington NHS Foundation Trust Not yet recruiting
Darlington, County Durham, United Kingdom, DL3 6HX
Contact: John G Silcock, MBBS, FRCP       john.silcock@cddft.nhs.uk   
Principal Investigator: John G Silcock, MBBS, FRCP         
North Cumbria University Hospitals NHS Trust Not yet recruiting
Carlisle, Cumbria, United Kingdom, CA2 7HY
Contact: Chris E MacDonald, MBBS FRCP    01228 814184    chris.macdonald@ncuh.nhs.uk   
Principal Investigator: Chris E MacDonald, MBBS FRCP         
Northumbria Healthcare NHS Trust Not yet recruiting
Ashington, Northumberland, United Kingdom, NE63 9JJ
Contact: Anthoor Jayaprakash       anthoor.jayaprakash@northumbria-healthcare.nhs.uk   
Principal Investigator: Anthoor Jayaprakash         
South Tees NHS Trust Not yet recruiting
Middlesbrough, Teeside, United Kingdom, TS4 3BW
Contact: Arvind Ramadas, MBBS, MRCP       arvind.ramadas@stees.nhs.uk   
Principal Investigator: Arvind Ramadas, MBBS, MRCP         
North Tees and Hartlepool NHS Foundation Trust Not yet recruiting
Stockton-on-Tees, Teeside, United Kingdom, TS19 8PE
Contact: Matthew D Rutter, MBChB MD    +44(0)1642 624557    matt.rutter@nth.nhs.uk   
Principal Investigator: Matthew D Rutter, MBChB MD         
Sponsors and Collaborators
South Tyneside NHS Foundation Trust
University of Durham
  More Information

Publications:
Hassan C, Pickard PJ, Rex DK. A resect and discard strategy would improve cost-effectiveness of colorectal cancer screening. Clin Gastroenterol Hepatol. 2010 Oct; 8 (10): 865-9, 9 e1-3.

Responsible Party: South Tyneside NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT01603927     History of Changes
Other Study ID Numbers: DISCARD2, PB-PG-1010-23222
Study First Received: May 17, 2012
Last Updated: May 22, 2012
Health Authority: United Kingdom: National Institute for Health Research

Additional relevant MeSH terms:
Colonic Polyps
Intestinal Polyps
Pathological Conditions, Anatomical
Polyps

ClinicalTrials.gov processed this record on November 24, 2014